TriangleNCT01536145 · OUTCOME
Single Dose End-of-infusion Concentration (Cinf) for CP-751,871
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- milligram/liter (mg/L)
- Interval / dispersion
- Standard Deviation
- Time frame
- 1 hour postdose in Cycle 1
Analysis population: All participants treated who had at least 1 concentration.
Groups in this outcome
CP-751,871 0.025 mg/kg
CP-751,871 0.025 milligram/kilogram (mg/kg) administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
CP-751,871 0.05 mg/kg
CP-751,871 0.05 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
CP-751,871 0.1 mg/kg
CP-751,871 0.1 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
CP-751,871 0.2 mg/kg
CP-751,871 0.2 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
CP-751,871 0.4 mg/kg
CP-751,871 0.4 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
CP-751,871 0.8 mg/kg
CP-751,871 0.8 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
CP-751,871 1.5 mg/kg
CP-751,871 1.5 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
CP-751,871 3 mg/kg
CP-751,871 3 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent Cycles, starting from Cycle 2 (4 weeks)
CP-751,871 6 mg/kg
CP-751,871 6 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
CP-751,871 10 mg/kg
CP-751,871 10 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks) and subsequent cycles, starting from Cycle 2 (4 weeks)
CP-751,871 20 mg/kg
CP-751,871 20 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks) and subsequent cycles, starting from Cycle 2 (4 weeks)
| Group | Source count |
|---|---|
| CP-751,871 0.025 mg/kg | 2 |
| CP-751,871 0.05 mg/kg | 4 |
| CP-751,871 0.1 mg/kg | 3 |
| CP-751,871 0.2 mg/kg | 3 |
| CP-751,871 0.4 mg/kg | 4 |
| CP-751,871 0.8 mg/kg | 2 |
| CP-751,871 1.5 mg/kg | 3 |
| CP-751,871 3 mg/kg | 4 |
| CP-751,871 6 mg/kg | 3 |
| CP-751,871 10 mg/kg | 7 |
| CP-751,871 20 mg/kg | 9 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| CP-751,871 0.025 mg/kg | 0 | NA | Not reported | Not reported | Number of participants analyzed was less than 3, thus standard deviation was not calculated. |
| CP-751,871 0.05 mg/kg | 0.381 | 0.448 | Not reported | Not reported | Not reported |
| CP-751,871 0.1 mg/kg | 5.32 | 6.85 | Not reported | Not reported | Not reported |
| CP-751,871 0.2 mg/kg | 5.36 | 1.52 | Not reported | Not reported | Not reported |
| CP-751,871 0.4 mg/kg | 6.66 | 2.84 | Not reported | Not reported | Not reported |
| CP-751,871 0.8 mg/kg | 14.6 | NA | Not reported | Not reported | Number of participants analyzed was less than 3, thus standard deviation was not calculated. |
| CP-751,871 1.5 mg/kg | 26.0 | 9.03 | Not reported | Not reported | Not reported |
| CP-751,871 3 mg/kg | 62.7 | 13.5 | Not reported | Not reported | Not reported |
| CP-751,871 6 mg/kg | 159 | 57.2 | Not reported | Not reported | Not reported |
| CP-751,871 10 mg/kg | 165 | 57.3 | Not reported | Not reported | Not reported |
| CP-751,871 20 mg/kg | 238 | 215 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- comment
- Number of participants analyzed was less than 3, thus standard deviation was not calculated.
- group Id
- OG000
- spread
- NA
- value
- 0
- group Id
- OG001
- spread
- 0.448
- value
- 0.381
- group Id
- OG002
- spread
- 6.85
- value
- 5.32
- group Id
- OG003
- spread
- 1.52
- value
- 5.36
- group Id
- OG004
- spread
- 2.84
- value
- 6.66
- comment
- Number of participants analyzed was less than 3, thus standard deviation was not calculated.
- group Id
- OG005
- spread
- NA
- value
- 14.6
- group Id
- OG006
- spread
- 9.03
- value
- 26.0
- group Id
- OG007
- spread
- 13.5
- value
- 62.7
- group Id
- OG008
- spread
- 57.2
- value
- 159
- group Id
- OG009
- spread
- 57.3
- value
- 165
- group Id
- OG010
- spread
- 215
- value
- 238
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 4
- group Id
- OG002
- value
- 3
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 4
- group Id
- OG005
- value
- 2
- group Id
- OG006
- value
- 3
- group Id
- OG007
- value
- 4
- group Id
- OG008
- value
- 3
- group Id
- OG009
- value
- 7
- group Id
- OG010
- value
- 9
- units
- Participants
- dispersion Type
- Standard Deviation
- groups
- description
- CP-751,871 0.025 milligram/kilogram (mg/kg) administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
- id
- OG000
- title
- CP-751,871 0.025 mg/kg
- description
- CP-751,871 0.05 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
- id
- OG001
- title
- CP-751,871 0.05 mg/kg
- description
- CP-751,871 0.1 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
- id
- OG002
- title
- CP-751,871 0.1 mg/kg
- description
- CP-751,871 0.2 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
- id
- OG003
- title
- CP-751,871 0.2 mg/kg
- description
- CP-751,871 0.4 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
- id
- OG004
- title
- CP-751,871 0.4 mg/kg
- description
- CP-751,871 0.8 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
- id
- OG005
- title
- CP-751,871 0.8 mg/kg
- description
- CP-751,871 1.5 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
- id
- OG006
- title
- CP-751,871 1.5 mg/kg
- description
- CP-751,871 3 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent Cycles, starting from Cycle 2 (4 weeks)
- id
- OG007
- title
- CP-751,871 3 mg/kg
- description
- CP-751,871 6 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
- id
- OG008
- title
- CP-751,871 6 mg/kg
- description
- CP-751,871 10 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks) and subsequent cycles, starting from Cycle 2 (4 weeks)
- id
- OG009
- title
- CP-751,871 10 mg/kg
- description
- CP-751,871 20 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks) and subsequent cycles, starting from Cycle 2 (4 weeks)
- id
- OG010
- title
- CP-751,871 20 mg/kg
- param Type
- MEAN
- population Description
- All participants treated who had at least 1 concentration.
- reporting Status
- POSTED
- time Frame
- 1 hour postdose in Cycle 1
- title
- Single Dose End-of-infusion Concentration (Cinf) for CP-751,871
- type
- SECONDARY
- unit Of Measure
- milligram/liter (mg/L)
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice